ILHAN YAYLIM | Cancer Genetics | Women Researcher Award

Posted on by ScienceFather

Prof. ILHAN YAYLIM | Cancer Genetics | Women Researcher Award

Instructer at Aziz sancar institute of Experimental medicine, Turkey

Prof. İlhan Yaylım is a distinguished academic specializing in molecular medicine and biochemistry, with extensive expertise in cancer biology and molecular genetics. He serves as a Professor at Istanbul University’s Aziz Sancar Institute of Experimental Medicine, where he contributes to groundbreaking research in fundamental medical sciences. With over two decades of academic and research experience, Prof. Yaylım has developed a significant body of work exploring the molecular mechanisms underlying various diseases, particularly cancer. He is a dedicated educator, imparting knowledge on cancer biology and molecular genetics through advanced postgraduate and doctoral courses. His extensive publication record, collaborations, and mentorship of graduate students underscore his commitment to advancing scientific inquiry and fostering the next generation of researchers.

Professional Profile

Education

Prof. Yaylım earned his undergraduate degree in Medical Biological Sciences from Istanbul University’s Cerrahpaşa Faculty of Medicine in 1991. He completed his postgraduate studies in Immunology at the Istanbul University Health Sciences Institute in 1995, focusing on purifying immunoglobulins using High-Performance Liquid Chromatography. He obtained his doctorate in Molecular Medicine in 2000 from the same institute, with a dissertation on the kinetic characterization of the CKI enzyme in normal and cancerous lung tissues and its relationship with Myc oncogene polymorphism. His comprehensive academic background has equipped him with a strong foundation in molecular medicine and translational research.

Professional Experience

Prof. Yaylım began his academic career as an Associate Professor at the Aziz Sancar Institute of Experimental Medicine, specializing in molecular medicine, a position he held from 2003 to 2010. Since 2010, he has been serving as a full Professor at the same institution. In addition to teaching and research, he has taken on administrative roles, contributing to the strategic growth of the institute. Prof. Yaylım has designed and delivered numerous postgraduate and doctoral courses, including those focused on cancer biology, molecular genetics, and clinical applications. His career reflects a deep commitment to academic excellence, innovation, and interdisciplinary collaboration.

Research Interests

Prof. Yaylım’s research interests lie at the intersection of medicine, biochemistry, and molecular genetics. He focuses on cancer biology, investigating gene polymorphisms, molecular pathways, and biomarkers associated with various cancers, including lung, breast, and colorectal cancers. His work extends to exploring the cellular and molecular mechanisms of diseases, aiming to identify novel therapeutic targets and diagnostic markers. Prof. Yaylım also has a keen interest in immunogenetics and translational research, aiming to bridge the gap between laboratory findings and clinical applications.

Research Skills

Prof. Yaylım possesses a diverse range of research skills, including advanced molecular biology techniques, such as gene polymorphism analysis, immunoglobulin purification, and enzyme kinetic characterization. He is proficient in utilizing High-Performance Liquid Chromatography (HPLC), molecular genetics tools, and clinical applications of molecular medicine. His expertise in supervising experimental research and mentoring graduate students demonstrates his ability to lead complex projects effectively. Additionally, his collaborative work with students on cancer biomarkers and gene variants reflects his strength in translational research.

Awards and Honors

Prof. Yaylım has received recognition for his contributions to molecular medicine and biochemistry through numerous academic and research accolades. His leadership in guiding groundbreaking studies and mentoring graduate students has solidified his reputation as a thought leader in the field. While specific awards are not listed, his appointment to esteemed positions, such as Professor at Istanbul University’s Aziz Sancar Institute, and his inclusion in international research platforms like ORCID and Publons, highlight his esteemed professional standing and contributions to advancing medical research.

Conclusion

Prof. İlhan Yaylım is a highly qualified researcher and academic with substantial contributions to cancer biology, molecular medicine, and biochemistry. His dedication to mentoring, teaching, and pioneering health sciences research positions him as a strong contender for the Excellence in Research Award. Addressing areas like international collaborations and global publication presence could enhance his candidature further.

Publication Top Notes

  1. Resveratrol-Loaded Silver Nanoparticles as an Effective Strategy for Targeted Breast Cancer Therapy”
    • Authors: Topçu, E., Hepokur, C., Afşin Kariper, İ., Emre Öksüz, K., Yaylim, İ.
    • Journal: ChemistrySelect
    • Year: 2024
  2. “IDO1-mediated catabolism of tryptophan in gastric tumors: Its potential role in the axis of histopathology, differentiation and metastasis”
    • Authors: Horozoglu, C., Hakan, M.T., Sonmez, D., Akyuz, F., Yaylim, I.
    • Journal: Pathology, Research and Practice
    • Year: 2024
  3. “Genetic Investigation of the Trail Mechanism in Diabetic and Non-diabetic Obese Patients”
    • Authors: Aksoyer Sezgin, S.B., Durak, S., Celik, F., Yaylim, I., Zeybek, U.
    • Journal: Biochemical Genetics
    • Year: 2024
  4. “TRAIL C1595T Variant Critically Alters the Level of sTRAIL in Terms of Histopathological Parameters in Colorectal Cancer”
    • Authors: Horozoglu, C., Yildiz, A., Sonmez, D., Arikan, S., Yaylim, I.
    • Journal: Indian Journal of Clinical Biochemistry
    • Year: 2024
  5. “Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications”
    • Authors: Yaylim, İ., Aru, M., Farooqi, A.A., Arese, M., Saso, L.
    • Journal: Cancer Drug Resistance
    • Year: 2024
    • Citations: 2
  6. “The analysis of Survivin promoter (−31G/C) gene variation in oral squamous cell carcinoma risk and prognosis”
    • Authors: Cacına, C., Akgün, A., Kayhan, K.B., Yaylım, İ., Çakmakoğlu, B.
    • Journal: Journal of Stomatology, Oral and Maxillofacial Surgery
    • Year: 2023
    • Citations: 3
  7. “Investigation of miR221 and miR222 as Biomarkers in Non-small Cell Lung Cancer”
    • Authors: Oltulu, Y.M., Coskunpinar, E., Yildiz, P., Karimova, A., Yaylim, I.
    • Journal: In Vivo
    • Year: 2023
    • Citations: 1
  8. “Plasma Levels of Kynurenine, Soluble OX40 and Mir-138-5p Are Associated With Tumor-infiltrating Lymphocytes in Colorectal Cancer: An Exploratory Study”
    • Authors: Zor, D.S., Hakan, M.T., Özgür, E., Gezer, U., Yaylim, I.
    • Journal: Anticancer Research
    • Year: 2023
    • Citations: 6
  9. “The influence of CASP8 D302H gene variant in colorectal cancer risk and prognosis”
    • Authors: Cacina, C., Sürmen, S.T., Arıkan, S., Pençe, S., Yaylım, İ.
    • Journal: Turkish Journal of Biochemistry
    • Year: 2023
  10. “lncRNA NORAD, soluble ICAM1 and their correlations may be related to the regulation of the tumor immune microenvironment in laryngeal squamous cell carcinoma (LSCC)”
    • Authors: Horozoglu, C., Bal, G., Kabadayı, B., Verim, A., Yaylım, İ.
    • Journal: Pathology Research and Practice
    • Year: 2023

 

Fatemeh Safari | Cancer Therapy | Women Researcher Award

Posted on by ScienceFather

Assist Prof Dr. Fatemeh Safari | Cancer Therapy | Women Researcher Award

Associate Professor at University of Guilan, Iran

Dr. Fatemeh Safari is an accomplished academic and researcher currently serving as an Associate Professor at the University of Guilan, Iran. She holds a Ph.D. in Molecular & Cellular Biology from Hokkaido University, Japan, and has extensive postdoctoral experience at prestigious institutions, including the University of Tokyo and NAIST. Dr. Safari has made significant contributions to the field of microbiology and cancer research, with numerous publications in reputable journals and books. Her work explores the molecular mechanisms underlying cancer progression and treatment, focusing on the therapeutic potential of stem cell secretomes and natural compounds like green tea extracts. Awarded multiple fellowships, including the JSPS Fellowship and Monbukagakusho Scholarship, she has established herself as a leading researcher. Dr. Safari’s expertise is complemented by her commitment to mentoring students and her active involvement in academic collaborations. Her research continues to impact the scientific community, enhancing our understanding of cancer biology and potential therapies.

Profile

Education

Assistant Professor Dr. Fatemeh Safari holds a Ph.D. in Molecular & Cellular Biology from Hokkaido University in Sapporo, Japan, where she completed her degree in 2011. Prior to her doctoral studies, she earned a Master’s degree in Microbiology from the University of Tehran in 2005, further solidifying her foundational knowledge in the biological sciences. Dr. Safari began her academic journey with a Bachelor’s degree in Biology, obtained from the University of Shahid Beheshti in Tehran, Iran, in 1999. Her diverse educational background encompasses a strong focus on molecular and cellular mechanisms, equipping her with the expertise necessary for her research in cancer biology and regenerative medicine. Dr. Safari’s academic achievements reflect her commitment to advancing scientific knowledge and contributing to the fields of microbiology and molecular biology.

Professional Experience

Prof. Dr. Fatemeh Safari has extensive experience in academia and research. Currently, she serves as an Associate Professor at the University of Guilan, Iran, since September 2022, where she has made significant contributions to the field of Molecular and Cellular Biology. Prior to this role, she was an Assistant Professor at the same institution from September 2016 to 2022. Dr. Safari gained valuable research experience as a Postdoctoral Fellow at prestigious institutions in Japan, including NAIST from 2014 to 2015 and The University of Tokyo from 2012 to 2014. Earlier in her career, she worked as a Research Assistant at the University of Tehran from 2005 to 2007. Throughout her career, Dr. Safari has focused on innovative research in microbiology and cancer biology, publishing extensively in reputable journals and contributing to various collaborative research projects. Her academic journey reflects her dedication to advancing scientific knowledge and mentoring future generations of researchers.

Research Interest

Professor Dr. Fatemeh Safari’s research interests lie at the intersection of molecular and cellular biology, with a particular focus on cancer biology, stem cell therapy, and drug development. Her work delves into understanding the molecular mechanisms underlying cancer progression and the potential therapeutic effects of mesenchymal stem cell (MSC) secretomes on various cancer types, including breast and colon cancers. Dr. Safari’s research also explores the modulation of cellular signaling pathways by natural and synthetic compounds, aiming to develop innovative anti-cancer agents. Her investigations into molecular docking, drug synthesis, and the bioactivity of green tea extracts highlight her commitment to finding novel therapeutic approaches. Additionally, she is involved in the development of advanced methodologies, such as spheroid formation and co-culture systems, to study tumor microenvironments. Dr. Safari’s research is highly interdisciplinary, contributing to the fields of oncology, pharmacology, and biotechnology.

Research Skills

Prof. Dr. Fatemeh Safari possesses a diverse array of research skills that significantly contribute to her expertise in molecular and cellular biology. Her extensive experience in microbiology and cancer research equips her with a robust foundation in experimental design and methodology. Proficient in advanced techniques such as molecular docking, cell culture, and the development of in vitro cancer models, she adeptly investigates cellular signaling pathways and the effects of various compounds on cancer cell behavior. Dr. Safari’s analytical skills are demonstrated through her numerous publications, showcasing her ability to synthesize complex data and draw meaningful conclusions. Additionally, her familiarity with both traditional and innovative approaches in microbiology allows her to explore interdisciplinary research opportunities. As a result, she is not only a proficient researcher but also a valuable mentor to emerging scientists, fostering a collaborative and innovative research environment in her laboratory.

Award and Recognition

Prof. Dr. Fatemeh Safari is a distinguished academic in the field of Molecular & Cellular Biology, recognized for her significant contributions to cancer research. She holds a Ph.D. from Hokkaido University and has garnered prestigious fellowships, including the Monbukagakusho Scholarship and the Japan Society for the Promotion of Science Fellowship. As an Associate Professor at the University of Guilan, she has published over 30 research articles in reputable journals and co-authored several book chapters, focusing on the molecular mechanisms of cancer and the therapeutic potential of stem cell secretomes. Her innovative research has earned her recognition within the academic community, and she actively participates in international conferences, sharing her findings and insights. Prof. Dr. Safari’s dedication to advancing scientific knowledge, coupled with her mentorship of emerging researchers, underscores her impactful role in the scientific community, making her a deserving candidate for the Best Researcher Award.

Conclusion

Professor Dr. Fatemeh Safari is a distinguished academic and researcher in the field of Molecular & Cellular Biology, with significant contributions to cancer research and regenerative medicine. Her extensive educational background, including a Ph.D. from Hokkaido University, complements her impressive publication record, featuring numerous articles in reputable journals. As an Associate Professor at the University of Guilan, she has demonstrated leadership in academia while mentoring students and collaborating on innovative research projects. Dr. Safari’s research focuses on the therapeutic potential of human adipose-derived mesenchymal stem cells (hAMSCs) in cancer treatment, highlighting her commitment to advancing scientific knowledge. Her recognition through prestigious fellowships, such as the JSPS Fellowship, underscores her international standing in the scientific community. With her blend of expertise, experience, and a dedication to research excellence, Professor Dr. Fatemeh Safari is a strong candidate for the Best Researcher Award, embodying the qualities of a leading scholar in her field.

Publication Top Notes
  1. Exploring the dichotomy of the mesenchymal stem cell secretome: Implications for tumor modulation via cell-signaling pathways
    • Authors: Rasouli, M., Alavi, M., D’Angelo, A., Roudi, R., Safari, F.
    • Year: 2024
    • Journal: International Immunopharmacology
    • Volume/Page: 143, 113265
    • Citations: 0
  2. Synthesis, molecular docking study, MD simulation, ADMET, and drug likeness of new thiazolo[3,2-a]pyridine-6,8-dicarbonitrile derivatives as potential anti-diabetic agents
    • Authors: Aghahosseini, F., Bayat, M., Sadeghian, Z., Gheidari, D., Safari, F.
    • Year: 2024
    • Journal: PLoS ONE
    • Volume/Issue/Page: 19(9), e0306973
    • Citations: 0
  3. TCAA-promoted novel approach synthesis and in vitro anti-cancer activity evaluation of spiro[indolo[2,1-b]quinazoline-6,4′-pyrano[2,3-c]pyrazole]-5′-carboxamides
    • Authors: Sadeghian, Z., Bayat, M., Eskandari, M., Safari, F.
    • Year: 2024
    • Journal: Results in Chemistry
    • Volume/Page: 9, 101636
    • Citations: 1
  4. The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells
    • Authors: Safari, F., Bararpour, S., Omidi Chomachaei, F.
    • Year: 2024
    • Journal: Investigational New Drugs
    • Volume/Issue/Page: 42(3), pp. 272–280
    • Citations: 1
  5. Regulation of Cellular-Signaling Pathways by Mammalian Proteins Containing Bacterial EPIYA or EPIYA-Like Motifs Predicted to be Phosphorylated
    • Authors: Rasouli, M., Safari, F., Sobhani, N., Alavi, M., Roudi, R.
    • Year: 2024
    • Journal: DNA and Cell Biology
    • Volume/Issue/Page: 43(2), pp. 74–84
    • Citations: 1
  6. IRTKS Elevation in Patients with Colon Cancer and the Curative Influences of Hamsc Secretome on Polarity and Invasion of HT-29 Colon Cancer Cells
    • Authors: Khodabandeh, A., Safari, F., Ebadi Zavieh, S., Mirzanejad, L.
    • Year: 2024
    • Journal: Regenerative Engineering and Translational Medicine
    • Citations: 0
  7. Harnessing Nanotechnology for Idarubicin Delivery in Cancer Therapy: Current Approaches and Future Perspectives
    • Authors: Safari, F., Jalalian, Y., Abdouss, H., Fathi-Karkan, S., Pandey, S.
    • Year: 2024
    • Journal: BioNanoScience
    • Citations: 2
  8. Synthesis, Molecular Docking, and Biological Evaluation of Pyridin-3-yl-Pyrimidin-2-yl-Triazole Derivatives as Anti-cancer Agents
    • Authors: Firoozpour, L., Moghimi, S., Fallah Barzegar, M.H., Safari, F., Foroumadi, A.
    • Year: 2024
    • Journal: Polycyclic Aromatic Compounds
    • Volume/Issue/Page: 44(3), pp. 2062–2076
    • Citations: 1
  9. Synthesis and Biological Evaluation of 12-Aryl-11-hydroxy-5,6-dihydropyrrolo[2″,1″:3′,4′]pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyridazine-8(9H)-one Derivatives as Potential Cytotoxic Agents
    • Authors: Barghi Lish, A., Foroumadi, A., Kolvari, E., Safari, F.
    • Year: 2023
    • Journal: ACS Omega
    • Volume/Issue/Page: 8(45), pp. 42212–42224
    • Citations: 1
  10. Evaluation of SgK269 expression in colon cancer patients and the effects of hAMSCs secretome on tumor invasion through SgK269/c-Src/p-P130Cas/p-Paxillin/p-ERK1/2 signaling pathway in HT-29 colon cancer cells
    • Authors: Safari, F., Ansari Dogaheh, F., Dadashi, H.
    • Year: 2023
    • Journal: 3 Biotech
    • Volume/Issue/Page: 13(11), 346
    • Citations: 1

 

 

Ranal Gurbanov | Cancer Research | Best Researcher Award

Posted on by ScienceFather

Mr. Ranal Gurbanov | Cancer Research | Best Researcher Award

Medical Student at Gazi University School of Medicine, Turkey.

Ranal Gurbanov, an Azerbaijani national born on May 2, 2004, is a promising young individual with a strong academic and humanitarian profile. He earned a bronze medal in the 2019 National Biology Olympiad and participated in the Future Leaders Exchange Program (FLEX) in the U.S., gaining valuable cultural and leadership experiences. Ranal has been recognized for academic excellence by the Baku Department of Education and is actively involved in community service through the “Social and Active Doctors Community (GÜTSAH)” and “KANOPE Blood and Organ Donation Community.” These roles demonstrate his commitment to supporting children with chronic diseases and raising awareness about blood and organ donation. Additionally, Ranal has pursued specialized medical training from prestigious institutions such as the University of Pennsylvania and Acıbadem University. His profile reflects a blend of academic achievement, leadership, and dedication to public health, though he would benefit from further research contributions to strengthen his candidacy for awards.

Profile:

Education

Ranal Gurbanov’s education reflects a strong commitment to academic excellence and personal growth. He began his educational journey with notable achievements at Baku High School No:102, where his exceptional talents earned him an Academic Excellence Award from the Baku Department of Education in 2021. Following this, Ranal participated in the Future Leaders Exchange Program (FLEX), which provided him with an opportunity to study at an American high school and experience a different educational and cultural environment. His commitment to furthering his knowledge is evident in his enrollment in various specialized medical training programs. These include “Vital Signs: Understanding What the Body Is Telling Us” by the University of Pennsylvania, “Clinical Terminology for International and U.S. Students” by the University of Pittsburgh, and several clinical risk management and forensic medicine courses offered by Acıbadem University. This diverse educational background highlights his dedication to both academic and practical learning.

Professional Experience

Ranal Gurbanov has actively engaged in various professional and extracurricular roles that reflect his commitment to both academic excellence and community service. He earned a bronze medal in the 2019 National Biology Olympiad, demonstrating his strong foundational knowledge in biology. His participation in the Future Leaders Exchange Program (FLEX) allowed him to study in the U.S., gaining invaluable cultural and leadership experience. In his volunteer work, Ranal has contributed to the “Social and Active Doctors Community (GÜTSAH),” where he helps improve the lives of children with chronic diseases through moral support and gifts. Additionally, his role in the “KANOPE” Blood and Organ Donation Community showcases his efforts to raise awareness about organ and blood donation, addressing critical healthcare issues in Turkey. His involvement in various medical training programs further highlights his dedication to understanding and improving clinical practices.

Research Interest

Ranal Gurbanov’s research interests are rooted in the intersection of biology, medical ethics, and community health. His early achievements in the National Biology Olympiad reflect a strong foundation in biological sciences, while his academic journey has been enriched by global experiences through the FLEX program, which broadened his understanding of diverse health systems. Ranal’s current focus includes exploring the ethical dimensions of organ donation and transplantation, a field he actively engages in through his role in the “KANOPE Blood and Organ Donation Community.” His interest also extends to clinical risk management and forensic medicine, evidenced by his participation in specialized training programs. Ranal is particularly motivated by addressing public health challenges and improving patient care through innovative approaches. His commitment to community service, coupled with his academic pursuits, underscores a desire to integrate scientific research with practical applications in healthcare.

Research Skills

Ranal Gurbanov has demonstrated a strong foundation in research through his participation in diverse educational and community activities. His involvement in the National Biology Olympiad and subsequent achievements highlight his solid grasp of biological sciences and scientific inquiry. Ranal’s engagement in specialized medical training programs, such as “Vital Signs” and “Clinical Risk Management,” reveals his commitment to understanding complex clinical concepts and research methodologies. Additionally, his role in organizing blood and organ donation awareness campaigns reflects his ability to translate scientific knowledge into public health initiatives. Although his profile is more focused on community service and humanitarian work, these experiences have honed his skills in communication, project management, and ethical considerations in healthcare. To further enhance his research skills, Ranal could benefit from direct involvement in scientific research projects and publications, which would solidify his expertise and contribute to his development as a researcher.

Award and Recognition

Ranal Gurbanov has received notable awards and recognition for his exceptional achievements and contributions. In 2019, he earned a bronze medal at the National Biology Olympiad organized by the Azerbaijan Ministry of Education, highlighting his early excellence in biological sciences. His leadership and adaptability were further recognized when he won the Future Leaders Exchange Program (FLEX) scholarship, allowing him to study in the U.S. and experience diverse cultural values. Additionally, he was honored with the Academic Excellence Award by the Baku Department of Education in 2021 for his outstanding academic performance at Baku High School No:102. Ranal’s commitment to social causes is evident through his active roles in the “Social and Active Doctors Community (GÜTSAH)” and the “KANOPE Blood and Organ Donation Community,” where he has contributed significantly to public health awareness and support for patients with chronic conditions.

Conclusion

Ranal Gurbanov shows tremendous potential and passion, especially in humanitarian and community-driven projects. However, to be a strong candidate for the Best Researcher Award, he needs to enhance his research output and demonstrate more direct contributions to the scientific field through publications or significant research findings. His commitment to learning and social impact is commendable, and with further academic and research development, he could emerge as a future contender.

Publication Top Notes

Ovatodiolide Inhibits Endometrial Cancer Stemness via Reactive Oxygen Species-Mediated DNA Damage and Cell Cycle Arrest

  • Journal: Chemico-Biological Interactions
  • Year: 2024
  • DOI: 10.1016/j.cbi.2024.111244
  • Authors: Chun-Yu Chen, Yu-Zhen Ye, Yu-Hao Huang, Yew-Min Tzeng, Ranal Gurbanov, Wen-Ling Wang, Wen-Wei Chang

 

Mrinal Ghosh | Cancer Biology | Best Researcher Award

Posted on by ScienceFather

Prof. Mrinal Ghosh | Cancer Biology | Best Researcher Award

Chief Scientist at CSIR-Indian Institute of Chemical Biology, India

Dr. Mrinal K. Ghosh is a distinguished Chief Scientist at the CSIR-Indian Institute of Chemical Biology and a Professor at AcSIR, New Delhi. With a Ph.D. in Biochemistry from the University of Calcutta, Dr. Ghosh specializes in cancer biology and inflammatory disorders. His extensive career includes leadership roles at CSIR-IICB and significant contributions to cancer research, particularly in glioma and breast cancer therapies. He has secured substantial funding for projects focusing on novel nanotechnology-based treatments and peptide therapeutics. Dr. Ghosh’s work has earned him prestigious awards such as the Bharat Vikash Award and recognition as a Fellow of the National Academy of Science & Technology. He is an active member of various scientific societies and has a robust publication record in high-impact journals. His research integrates advanced molecular biology techniques and translational medicine to address critical challenges in oncology.

Profile

Education

Dr. Mrinal K. Ghosh completed his education with a strong foundation in biochemistry and molecular biology. He earned his Ph.D. in Biochemistry from the University of Calcutta, India, where he conducted extensive research in the field from 1991 to 1997. Prior to his doctoral studies, Dr. Ghosh obtained his Master of Science degree in Biochemistry, with a focus on Molecular Biology, from the same institution in 1990. His undergraduate studies were in Chemistry, with honors, complemented by Physics and Mathematics, also at the University of Calcutta, culminating in his Bachelor of Science degree in 1988. Dr. Ghosh’s academic journey laid a solid groundwork for his subsequent research and leadership roles in cancer biology and inflammatory disorders, significantly contributing to his reputation as a leading scientist in his field.

Professional Experience

Dr. Mrinal K. Ghosh is a distinguished scientist with a remarkable career in cancer biology and inflammatory disorders. Currently serving as the Chief Scientist and Head of the Cancer Biology & Inflammatory Disorder Division at CSIR-Indian Institute of Chemical Biology (CSIR-IICB), he has been instrumental in advancing research in these fields. Prior to this role, he held positions as Senior Principal Scientist and Principal Scientist at CSIR-IICB, showcasing a trajectory of increasing responsibility. His earlier career included roles as Senior Lecturer at the Department of Biotechnology, HIT, Kolkata, and research positions at the Cleveland Clinic Foundation in the USA. Dr. Ghosh’s extensive experience includes leading significant research projects, managing research teams, and contributing to scientific advancements through his various roles and memberships in professional societies. His career is marked by his dedication to translating scientific discoveries into therapeutic innovations.

Research Interest

Dr. Mrinal K. Ghosh’s research interests focus on advancing cancer biology and inflammatory disorders through innovative biochemical and molecular approaches. His work emphasizes understanding the molecular mechanisms underlying cancer progression, particularly in glioma and breast cancer. Dr. Ghosh investigates the roles of key proteins and signaling pathways, including the p53 and Rb tumor suppressor proteins, and the ubiquitin-proteasome system in regulating cancer cell behavior. His research integrates nanotechnology and peptide therapeutics to develop novel treatment strategies, aiming to enhance the effectiveness of current therapies and overcome resistance. Additionally, Dr. Ghosh explores the implications of cancer biology in the context of stem cell research and neurodegenerative diseases. His comprehensive approach combines preclinical validation, clinical insights, and cutting-edge technology to address critical challenges in cancer treatment and provide new avenues for therapeutic interventions.

Research Skills

Dr. Mrinal K. Ghosh demonstrates exceptional research skills in the field of cancer biology and inflammatory disorders. His expertise spans molecular and cellular mechanisms, particularly in signal transduction related to cancer and stem cells. Dr. Ghosh is proficient in advanced techniques such as nanotechnology-based therapeutic systems, biomolecular target identification, and peptide therapeutic design. His research includes pre-clinical validation of therapies, focusing on glioma and breast cancer, utilizing sophisticated methods like protein modification and nanoparticle-based delivery systems. Dr. Ghosh’s ability to lead large-scale, multi-disciplinary projects is evident from his successful management of significant research grants and collaborations. His extensive publication record in high-impact journals and his role as a reviewer for leading scientific journals highlight his critical analytical skills and contribution to the scientific community. His innovative approach and comprehensive understanding of cancer biology underscore his research prowess.

Award and Recognition

Dr. Mrinal K. Ghosh has garnered significant recognition for his pioneering research in cancer biology and inflammatory disorders. His contributions have been acknowledged through numerous prestigious awards, including the Bharat Vikash Award in 2019, which honors outstanding achievements in scientific research. Dr. Ghosh is also a Fellow of the National Academy of Science & Technology (FNASc) and the Academy of Science & Technology (FAScT), reflecting his esteemed status within the scientific community. His research excellence is further underscored by his role as the Principal Investigator in several high-impact projects, such as the PAN-CSIR Cancer Research initiative and various DST-Nano Mission projects. Additionally, Dr. Ghosh has been honored with the Outstanding Scientist Award on Strategic Management and Business Strategy in 2023. These accolades, coupled with his extensive contributions to scientific literature and research, solidify his standing as a leading figure in his field.

Conclusion

Dr. Mrinal K. Ghosh is highly deserving of the Best Researcher Award due to his outstanding contributions to cancer biology and inflammatory disorders, as evidenced by his awards, extensive research funding, and high-impact publications. His leadership roles and recognition in the scientific community further underscore his excellence. Addressing areas such as enhancing international collaborations and increasing public engagement could further amplify his impact and align with broader scientific and societal goals.

Publications Top Notes

  1. MGMT in TMZ-based Glioma therapy: Multifaceted Insights and Clinical Trial Perspectives
    • Authors: Shaw R, Basu M, Karmakar S, Ghosh MK*
    • Journal: BBA – Molecular Cell Research
    • Year: 2024
    • Volume and Issue: 1871, 119673
    • Impact Factor: 5.1
    • Citations: 0
  2. Chromosomal instability (CIN) triggers immune evasion and metastatic potential in cancer through rewired STING signalling
    • Authors: Ghosh MK*, Roy S
    • Journal: Molecular Biomedicine
    • Year: 2024
    • Volume and Issue: 5(4)
    • Impact Factor: 6.0
    • Citations: 0
  3. E3 Ubiquitin Ligases in Lung Cancer: Emerging Insights and Therapeutic Opportunities
    • Authors: Basu B, Kal S, Karmakar S, Basu M, Ghosh MK*
    • Journal: Life Sciences
    • Year: 2024
    • Volume and Issue: 336, 122333
    • Impact Factor: 6.1
    • Citations: 0
  4. Carbon Nanotubes in Cancer Diagnosis and Treatment: Current Trends and Future Perspectives
    • Authors: Kumar S#, Ansari A#, Basu M#, Ghosh S#, Begam S#, Ghosh MK#*
    • Journal: Advanced Therapeutics
    • Year: 2024
    • Impact Factor: 4.6
    • Citations: 0
    • Status: In press
  5. E3 ubiquitin ligases and deubiquitinases in colorectal cancer: Emerging molecular insights and therapeutic opportunities
    • Authors: Kumar S, Basu M, Ghosh MK*
    • Journal: BBA – Molecular Cell Research
    • Year: 2024
    • Volume and Issue: 1871, 119673
    • Impact Factor: 5.1
    • Citations: 0
    • Status: In press
  6. Glioma Immunotherapy: Exploring Molecular and Clinical Frontiers
    • Authors: Ghosh MK*, Kumar S, Begam S, Ghosh S, Basu M
    • Journal: Life Sciences
    • Year: 2024
    • Impact Factor: 5.2
    • Citations: 0
    • Status: In press
  7. Glioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ
    • Authors: Sarkar S#, Kumar S#, Saha G, Basu M, Ghosh MK*
    • Journal: International Journal of Pharmaceutics
    • Year: 2024
    • Impact Factor: 5.3
    • Citations: 0
    • Status: Under Review (R1)
  8. Unraveling COVID-19 diagnostics: A roadmap for future pandemic
    • Authors: Kumar S, Basu M*, Chakraborty D, Ghosh P, Bajoria S, Ghosh MK*
    • Journal: Nature Cell & Sciences
    • Year: 2024
    • Status: Under Review

2023 Publications:

  1. USP7 – A crucial regulator of Cancer Hallmarks
    • Authors: Saha G, Roy S, Basu M, Ghosh MK*
    • Journal: BBA – Reviews on Cancer
    • Year: 2023
    • Volume and Issue: 1878, 188903
    • Impact Factor: 11.2
    • Citations: 10
  2. Neurological damages in COVID-19 patients: mechanisms and preventive interventions
    • Authors: Sarkar S#, Karmakar S#, Basu M, Ghosh P, Ghosh MK*
    • Journal: MedComm
    • Year: 2023
    • Volume and Issue: 4, e247,1-25
    • Impact Factor: 10.7
    • Citations: 10

 

Jaclyn Gellings | Breast Cancer | Best Researcher Award

Posted on by ScienceFather

Dr. Jaclyn Gellings | Breast Cancer | Best Researcher Award

Surgical Research Resident at Medical College of Wisconsin, United States

Jaclyn Gellings, MD, is a distinguished General Surgery Resident and Global Surgery Research Fellow at the Medical College of Wisconsin. She holds a BS from the University of Wisconsin and an MD from the Medical College of Wisconsin. Gellings has garnered notable accolades, including the Condon Donegan Research Award and the MCWAH Research and Quality Award, reflecting her research excellence. Her work focuses on trauma care and surgical procedures, with significant publications and grant-funded projects. She actively participates in global health initiatives, including fellowships and rotations in Nepal and Ireland, demonstrating her commitment to improving healthcare worldwide. Gellings is also engaged in professional societies and has held leadership roles, contributing to the advancement of her field. Her extensive research, international experience, and leadership make her a standout candidate for the Researcher Award, showcasing her dedication to medical innovation and global health improvement.

Profile

Education

Jaclyn Gellings, MD, has a distinguished educational background that underscores her commitment to medicine and surgery. She earned her Bachelor of Science degree from the University of Wisconsin-Madison in May 2015, where she laid the foundation for her medical career. Following her undergraduate studies, she pursued her Doctor of Medicine degree at the Medical College of Wisconsin, graduating in May 2020. Her educational journey continued with advanced postgraduate training as a General Surgery Resident at the Medical College of Wisconsin, where she has been honing her clinical and research skills since July 2020. Currently, she is further advancing her expertise through a Global Surgery Research Fellowship at the same institution, set to conclude in June 2025. This extensive educational experience has equipped Dr. Gellings with a robust clinical acumen and a strong research focus, positioning her as a leading figure in her field.

Professional Experience

Jaclyn Gellings, MD, currently serves as a General Surgery Resident and Global Surgery Research Fellow at the Medical College of Wisconsin. Her postgraduate training includes a residency in General Surgery and a prestigious fellowship in Global Surgery Research, focusing on trauma and acute care. Dr. Gellings has received notable awards such as the Condon Donegan Research Award and the MCWAH Research and Quality Award, underscoring her research excellence. Her work has been supported by significant grants, including a $49,823 grant for characterizing surgical paths for uninsured patients. She has been involved in various leadership roles, including serving as a Resident Board Member for the Wisconsin Medical Society and a member of the Global Affairs Committee for the Association for Academic Surgery. Her research contributions are well-recognized, with numerous peer-reviewed publications and presentations at national and international conferences.

Research Interest

Jaclyn Gellings, MD, focuses her research on trauma and acute care surgery, with particular interest in optimizing surgical practices and improving patient outcomes. Her work encompasses various aspects of trauma care, including the cost-effectiveness of diagnostic testing and the impact of prophylactic treatments. Gellings is also dedicated to global health, exploring surgical needs and interventions in underserved regions such as Nepal and Ireland. Her research extends to the implementation of evidence-based guidelines in trauma care and the evaluation of surgical procedures like the Norwood procedure in pediatric cardiology. Through her Global Surgery Research Fellowship, Gellings aims to advance surgical care on an international scale, addressing disparities and enhancing the quality of care in diverse settings. Her contributions reflect a commitment to both clinical excellence and global health improvement, demonstrating a comprehensive approach to advancing the field of surgery.

Research Skills

Jaclyn Gellings, MD, demonstrates exceptional research skills through her comprehensive and impactful work in the field of surgery. Her expertise spans clinical research, evidenced by her significant contributions to trauma and acute care surgery, including cost-saving initiatives and procedural improvements. Gellings excels in designing and conducting studies that address critical healthcare challenges, as reflected in her peer-reviewed publications and competitive research grants. Her role in the Global Surgery Research Fellowship highlights her proficiency in managing and executing research projects on an international scale. Additionally, her experience with various research methodologies, from clinical trials to data analysis, underscores her versatility and depth of knowledge. Gellings’ ability to communicate complex findings through invited lectures and peer-reviewed presentations further illustrates her strong analytical skills and commitment to advancing medical science. Her well-rounded research capabilities are complemented by her leadership in academic and professional societies, reinforcing her status as a leading researcher in her field.

Award and Recognition

Jaclyn Gellings, MD, has garnered notable awards and recognition throughout her medical and research career. She received the 2022 Condon Donegan Research Award and the MCWAH Research and Quality Award for her impactful research contributions. Gellings also earned the Maryann Zwaska Schmitz Endowed Scholarship Fund for Surgery in 2020 and multiple scholarships during her time at the University of Wisconsin, Madison. Her dedication to research and academic excellence is further highlighted by her Honors in Research from the Medical College of Wisconsin. As an active member of professional societies, including the Eastern Association for the Surgery of Trauma and the Association for Academic Surgery, she has been acknowledged for her leadership and commitment to advancing surgical practice. Gellings’ global health initiatives and significant research funding further underscore her exceptional contributions to the field.

Conclusion

Jaclyn Gellings is a highly qualified candidate for the Researcher Award, given her strong research background, significant contributions to the field of surgery, and active role in global health initiatives. Her achievements reflect a deep commitment to improving surgical care and addressing global health challenges. By expanding her publication impact and engaging in broader collaborations, she can further strengthen her position as a leading researcher. Overall, her record of accomplishment and dedication make her a compelling candidate for this prestigious award.

Publication Top Notes

  • Thoracic cavity irrigation prevents retained hemothorax and decreases surgical intervention in trauma patients
    • Authors: Al Tannir, A.H., Biesboer, E.A., Golestani, S., De Moya, M.A., Carver, T.W.
    • Journal: Journal of Trauma and Acute Care Surgery
    • Year: 2024
    • Volume and Issue: 97(1), pp. 90–95
  • Benign mature teratoma of the cecum: A case report
    • Authors: Gellings, J., Nimmer, K., Doucette, S., Johnson, S.C., Kothari, A.N.
    • Journal: Journal of Surgical Case Reports
    • Year: 2023
    • Volume and Issue: 2023(12), rjad674
  • Annual cost-savings with the implementation of estrogen-receptor-only testing on Ductal Carcinoma in Situ specimens
    • Authors: Gellings, J.A., Cortina, C.S., Jorns, J.M., Huang, C.-C., Kong, A.L.
    • Journal: American Journal of Surgery
    • Year: 2023
    • Volume and Issue: 225(2), pp. 304–308
  • Norwood Procedure—Difficulty in Weaning From Cardiopulmonary Bypass and Implications for Outcomes
    • Authors: Gellings, J.A., Johnson, W.K., Ghanayem, N.S., Kuhn, E.M., Woods, R.K.
    • Journal: Seminars in Thoracic and Cardiovascular Surgery
    • Year: 2020
    • Volume and Issue: 32(1), pp. 119–125
    • Citations: 2
  • Design considerations in coiled-coil fusion constructs for the structural determination of a problematic region of the human cardiac myosin rod
    • Authors: Andreas, M.P., Ajay, G., Gellings, J.A., Rayment, I.
    • Journal: Journal of Structural Biology
    • Year: 2017
    • Volume and Issue: 200(3), pp. 219–228
    • Citations: 3

 

Jaydira Del Rivero | Medical Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Jaydira Del Rivero | Medical Oncology | Best Researcher Award

MD of NCI/NIH, United States.

Dr. Jaydira Del Rivero has a robust set of research skills tailored for oncology. Her expertise includes cell culture, immunohistochemistry, CRISPR/Cas9 gene editing, and advanced microscopy. Proficient in data analysis using SPSS and R, she excels in bioinformatics for genomic data. Dr. Del Rivero is adept at experimental design, critical literature evaluation, and communicating scientific results.

Professional Profiles:

Education

Dr. Jaydira Del Rivero earned her Doctor of Medicine (MD) degree from the University of Veracruz, Faculty of Medicine “Lic. Miguel Aleman Valdez” in October 2003. She completed her Internal Medicine residency at Woodhull Medical and Mental Health Center/NYU Langone Medical Center in Brooklyn, NY, from July 2008 to June 2011. Following this, she pursued a fellowship in Endocrinology, Diabetes, and Metabolism at the Inter-Institute Adult Endocrine Training Program at the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, from July 2011 to June 2014. Dr. Del Rivero further specialized in Medical Oncology through a fellowship at the National Cancer Institute, National Institutes of Health, Bethesda, MD, from July 2015 to June 2017. Her extensive training reflects her deep commitment to advancing in both endocrinology and oncology.

Professional Experience

Dr. Jaydira Del Rivero has held several notable positions in the medical field. She began her career as a Medical Officer at the National Institute of Child Health and Human Development from August 2014 to June 2015, where she focused on endocrine research. Following her fellowship in Medical Oncology, she joined the National Cancer Institute (NCI) as a Clinical Fellow in the Medical Oncology Branch from July 2015 to June 2017. Since 2017, Dr. Del Rivero has been a Medical Oncologist at the NCI, specializing in the treatment and research of cancer. Her role involves clinical practice, patient management, and contributing to ongoing research efforts. Dr. Del Rivero’s work is pivotal in advancing the understanding and treatment of oncology-related conditions.

Research Interest

Dr. Jaydira Del Rivero’s research interests are centered around oncology, with a particular focus on advancing the understanding and treatment of cancer. Her work primarily explores endocrine-related malignancies, including the development of novel therapeutic strategies and treatment protocols. Dr. Del Rivero is involved in researching the mechanisms of cancer progression and resistance to treatments, aiming to improve patient outcomes through innovative approaches. Her research also encompasses the evaluation of new drugs and treatment regimens, with a commitment to integrating clinical findings with experimental data to enhance therapeutic efficacy. Through her work at the National Cancer Institute, she contributes to cutting-edge studies that aim to address critical challenges in cancer care and therapy.

Award and Honors

Dr. Jaydira Del Rivero has received several notable awards and honors for her contributions to oncology research. She was recognized with the prestigious NCI Director’s Award in 2021 for her exceptional work in cancer research and her commitment to advancing treatment options. In 2019, she earned the American Association for Cancer Research (AACR) Scholar Award, which acknowledged her innovative research on endocrine-related cancers. Additionally, Dr. Del Rivero was honored with the National Cancer Institute’s Outstanding Research Award in 2018 for her impactful studies on novel therapeutic strategies. Her achievements reflect her dedication to improving cancer care and her significant contributions to the field of oncology.

 Research Skills

Dr. Jaydira Del Rivero possesses advanced research skills essential for her work in oncology. She is proficient in various laboratory techniques including cell culture, immunohistochemistry, and molecular cloning. Her expertise extends to cutting-edge methods such as CRISPR/Cas9 gene editing and advanced microscopy techniques. Dr. Del Rivero is skilled in data analysis and statistical software such as SPSS and R, which she utilizes for interpreting complex research data. She also has experience with bioinformatics tools for genomic data analysis, enabling her to identify novel biomarkers and therapeutic targets. Her research skills are complemented by a strong ability to design and conduct experiments, critically evaluate scientific literature, and effectively communicate findings through publications and presentations.

Publications
  1. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
    Authors: E Wong, LS Rosen, M Mulay, A VanVugt, M Dinolfo, C Tomoda, …
    Journal: Thyroid
    Year: 2007
    Volume/Issue: 17 (4), 351-355
    Citations: 238
  2. The Bethesda handbook of clinical oncology
    Authors: J Abraham, JL Gulley
    Publisher: Lippincott Williams & Wilkins
    Year: 2022
    Citations: 158
  3. Anti–PD-L1 treatment induced central diabetes insipidus
    Authors: C Zhao, SH Tella, J Del Rivero, A Kommalapati, I Ebenuwa, J Gulley, …
    Journal: The Journal of Clinical Endocrinology & Metabolism
    Year: 2018
    Volume/Issue: 103 (2), 365-369
    Citations: 104
  4. Tyrosine kinase inhibitor–induced thyroid disorders: a review and hypothesis
    Authors: N Makita, T Iiri
    Journal: Thyroid
    Year: 2013
    Volume/Issue: 23 (2), 151-159
    Citations: 99
  5. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors
    Authors: AM Rosenberg, P Friedmann, J Del Rivero, SK Libutti, AM Laird
    Journal: Surgery
    Year: 2016
    Volume/Issue: 159 (1), 302-310
    Citations: 93
  6. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis‐hyperphosphatemia syndrome
    Authors: MS Ramnitz, P Gourh, R Goldbach‐Mansky, F Wodajo, S Ichikawa, …
    Journal: Journal of Bone and Mineral Research
    Year: 2016
    Volume/Issue: 31 (10), 1845-1854
    Citations: 87
  7. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma
    Authors: L Fishbein, J Del Rivero, T Else, JR Howe, SL Asa, DL Cohen, PLM Dahia, …
    Journal: Pancreas
    Year: 2021
    Volume/Issue: 50 (4), 469-493
    Citations: 77
  8. Novel insights into the polycythemia–paraganglioma–somatostatinoma syndrome
    Authors: R Därr, J Nambuba, J Del Rivero, I Janssen, M Merino, M Todorovic, …
    Journal: Endocrine-Related Cancer
    Year: 2016
    Volume/Issue: 23 (12), 899-908
    Citations: 76
  9. Endocrine‐related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management
    Authors: J Del Rivero, LM Cordes, J Klubo‐Gwiezdzinska, RA Madan, LK Nieman, …
    Journal: The Oncologist
    Year: 2020
    Volume/Issue: 25 (4), 290-300
    Citations: 72
  10. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report
    Authors: JE Faris, AF Moore, GH Daniels
    Journal: Thyroid
    Year: 2007
    Volume/Issue: 17 (11), 1147-1149
    Citations: 72

 

 

Mohammed Kashani-Sabet | Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Mohammed Kashani-Sabet | Oncology | Best Researcher Award

Medical Director, Oncology Service Line, Sutter Health at California Pacific Medical Center Research Institute, United States.

Dr. Mohammed Kashani-Sabet is a distinguished medical professional with extensive expertise in dermatology and oncology. Holding multiple leadership positions, including Medical Director of the Oncology Service Line at Sutter Health and the Cancer Center at California Pacific Medical Center, he has made significant contributions to cancer research and treatment. Dr. Kashani-Sabet received his medical education from renowned institutions such as Harvard University and the State University of New York at Stony Brook. Throughout his career, he has been involved in groundbreaking research focused on melanoma, cutaneous T-cell lymphoma, targeted therapy, and tumor biomarkers. He has received numerous honors and awards for his contributions to the field, including the Clinical Career Development Award from the Dermatology Foundation and the Patients’ Choice Award by Sutter Medical Network. Dr. Kashani-Sabet’s dedication to improving patient care and advancing cancer treatment has earned him widespread recognition and respect in the medical community.

Professional Profiles:

Education:

Dr. Mohammed Kashani-Sabet embarked on his academic journey with a Bachelor’s degree in Biochemical Sciences from Harvard University, followed by a Doctorate in Medicine from the State University of New York at Stony Brook. After completing his medical education, he undertook an internship in Internal Medicine and residency in Dermatology at the State University of New York at Stony Brook and the University of California, San Francisco (UCSF) respectively. Dr. Kashani-Sabet further honed his expertise through a post-doctoral fellowship in Cutaneous Oncology at UCSF’s Department of Dermatology and Division of Hematology/Oncology. This comprehensive educational background laid a robust foundation for his subsequent career as a renowned physician and researcher in the field of dermatology and oncology.

Professional Experience:

Dr. Mohammed Kashani-Sabet has held several prestigious positions throughout his career, demonstrating his leadership and expertise in the field of dermatology and oncology. Currently, he serves as the Medical Director of the Oncology Service Line at Sutter Health and as the Medical Director of the Cancer Center at California Pacific Medical Center. Additionally, he holds the position of Medical Director of the Center for Melanoma Research and Treatment at Sutter West Bay Medical Group, Sutter Pacific Medical Foundation, and California Pacific Medical Center. Dr. Kashani-Sabet also contributes significantly to research as a Senior Scientist at the California Pacific Medical Center Research Institute. His extensive professional experience spans over two decades and encompasses various roles in academia, clinical practice, and administrative leadership within prestigious institutions such as the University of California, San Francisco (UCSF) and the California Pacific Medical Center.

Research Focus:

Dr. Mohammed Kashani-Sabet’s research focus encompasses a broad spectrum of topics within dermatology and oncology, with a particular emphasis on melanoma and cutaneous T-cell lymphoma. His work includes investigating novel targeted therapies, such as ribozymes and siRNAs, for these malignancies. Additionally, he explores tumor metastasis, prognostic modeling, and tumor biomarkers to advance our understanding of these diseases and improve patient outcomes. Dr. Kashani-Sabet’s research efforts aim to translate scientific discoveries into clinical applications, with the ultimate goal of developing more effective treatments and interventions for patients with melanoma and cutaneous T-cell lymphoma.

Research Interest:

Dr. Mohammed Kashani-Sabet possesses a diverse set of research skills honed over years of experience in dermatology and oncology. His expertise includes clinical research, where he designs and conducts studies to evaluate novel therapies for melanoma and cutaneous T-cell lymphoma. In the laboratory, he is skilled in various techniques such as PCR, DNA sequencing, and gene expression analysis, essential for basic and translational research. Dr. Kashani-Sabet also excels in data analysis, utilizing statistical methods and software to interpret clinical and experimental data effectively. With a track record of publishing research findings in peer-reviewed journals, he demonstrates proficiency in scientific writing and manuscript preparation. Additionally, his ability to write grant proposals and collaborate with interdisciplinary teams underscores his commitment to advancing dermatologic oncology research and improving patient care.

Award and Honors:

Dr. Mohammed Kashani-Sabet has been recognized with numerous awards and honors throughout his career, reflecting his exceptional contributions to dermatologic oncology research and patient care. Among these accolades are the Clinical Career Development Award from the Dermatology Foundation in 1997 and the Herschel and Diana Zackheim Endowed Chair in Cutaneous Oncology in the same year. His dedication to teaching and mentorship was acknowledged with the Teacher of the Year Award in 2004, bestowed upon him by the Dermatology Residents at UCSF. Notably, Dr. Kashani-Sabet received the Patients’ Choice Award in 2013 from the Sutter Medical Network for achieving high patient satisfaction scores. His humanitarian efforts were recognized with the Humanitarian Award by the Melanoma Research Foundation in 2014. Moreover, he holds the Chair in Melanoma Research and Treatment at California Pacific Medical Center since 2015, a testament to his leadership and contributions to the field.

Publications:

  1. Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
    • Authors: Chang, S.H., Ice, R.J., Chen, M., … Soroceanu, L., McAllister, S.D.
    • Citations: 0
    • Year: 2023
  2. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing
    • Authors: Kashani-Sabet, M., Leachman, S.A., Stein, J.A., … Venna, S., Kirkwood, J.M.
    • Citations: 6
    • Year: 2023
  3. Improving Selection for Sentinel Lymph Node Biopsy among Patients with Melanoma
    • Authors: Miller, J.R., Lo, S.N., Nosrati, M., … Scolyer, R.A., Kashani-Sabet, M.
    • Citations: 3
    • Year: 2023
  4. Erratum: Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma
    • Authors: Dar, A.A., Bezrookove, V., Nosrati, M., … McAllister, S., Kashani-Sabet, M.
    • Citations: 0
    • Year: 2023
  5. Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment
    • Authors: Sidorov, M., Dighe, P., Woo, R.W.L., … McAllister, S.D., Soroceanu, L.
    • Citations: 7
    • Year: 2023
  6. Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas
    • Authors: Minor, D.R., Kim, K.B., Karuturi, R.K.M., Kashani-Sabet, M.
    • Citations: 0
    • Year: 2023
  7. Lymphoscintigraphy Using Tilmanocept Detects Multiple Sentinel Lymph Nodes in Melanoma Patients
    • Authors: Balkin, D.M., Tranah, G.J., Wang, F., … Zager, J.S., Leong, S.P.
    • Citations: 0
    • Year: 2023
  8. BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target
    • Authors: Bezrookove, V., Khan, I.A., Nosrati, M., … Dar, A.A., Kashani-Sabet, M.
    • Citations: 3
    • Year: 2022
  9. Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience
    • Authors: Chen, M., Jian, D., Sidorov, M., … McAllister, S.D., Desprez, P.-Y.
    • Citations: 2
    • Year: 2022
  10. Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma
    • Authors: Dar, A.A., Bezrookove, V., Nosrati, M., … McAllister, S., Kashani-Sabet, M.
    • Citations: 3
    • Year: 2022